ストックスクリーナーアプリを入手
9.65
2.53%
-0.25
アフターアワーズ：
9.75
0.10
+1.04%
前日終値:
$9.90
開ける：
$10.05
24時間の取引高:
2.28M
Relative Volume:
1.36
時価総額：
$958.28M
収益：
$98.99M
当期純損益:
$-197.98M
株価収益率:
-4.8209
EPS:
-2.0017
ネットキャッシュフロー:
$-175.32M
1週間 パフォーマンス:
+0.63%
1か月 パフォーマンス:
+32.19%
6か月 パフォーマンス:
-1.73%
1年 パフォーマンス:
-39.35%
1日の値動き範囲:
$9.50
$10.25
1週間の範囲:
$9.50
$10.25
52週間の値動き範囲:
$6.66
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
名前
Ars Pharmaceuticals Inc
セクター
電話
858-771-9307
住所
11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
Compare SPRY vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
9.65 | 958.28M | 98.99M | -197.98M | -175.32M | -2.0017 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-09 | 開始されました | Northland Capital | Outperform |
| 2025-11-04 | 再開されました | Roth Capital | Buy |
| 2025-09-04 | 開始されました | Roth Capital | Buy |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2025-02-10 | 開始されました | Oppenheimer | Outperform |
| 2024-08-20 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-08-13 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | 繰り返されました | Leerink Partners | Outperform |
| 2024-07-25 | 開始されました | Raymond James | Outperform |
| 2024-03-05 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | 開始されました | Wedbush | Outperform |
| 2023-01-03 | 開始されました | William Blair | Outperform |
| 2022-12-13 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Ars Pharmaceuticals Inc (SPRY) 最新ニュース
(SPRY) Risk Channels and Responsive Allocation - Stock Traders Daily
ARS Pharmaceuticals Inc (SPRY) Institutional Confidence - TradingKey
ARS Pharmaceuticals Inc (SPRY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ARS Pharmaceuticals Inc (SPRY) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ARS Pharmaceuticals Inc (SPRY) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ARS Pharmaceuticals Inc (SPRY) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ARS Pharmaceuticals Inc (SPRY) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ARS Pharmaceuticals Inc (SPRY) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ARS Pharmaceuticals Inc (SPRY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Insider Sell: Eric Karas Sells 25,000 Shares of ARS Pharmaceuticals Inc (SPRY) - GuruFocus
Ars Pharmaceuticals CLO Alexander Fitzpatrick sells $33,550 in stock - Investing.com UK
Ars Pharmaceuticals CLO Alexander Fitzpatrick sells $33,550 in stock By Investing.com - Investing.com Nigeria
ARS Pharmaceuticals CCO Eric Karas sells $250,000 in stock By Investing.com - Investing.com Australia
ARS Pharmaceuticals CCO Eric Karas sells $250,000 in stock - Investing.com
ARS Pharmaceuticals (SPRY) legal chief sells 3,355 shares in planned trade - Stock Titan
[144] ARS Pharmaceuticals, Inc. SEC Filing - Stock Titan
SPRY Should I Buy - Intellectia AI
From Clinical To Market: Managing Pharma's Most Challenging Transition - Life Science Leader
How The Evolving Story For ARS Pharmaceuticals (SPRY) Could Shape Future Valuation - Yahoo Finance
ARS Pharmaceuticals, Inc. (SPRY) soars 7.1%: Is further upside left in the stock? - MSN
(SPRY) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies - The Manila Times
Drew Brees on living with food allergies and needle-free epinephrine - Stock Titan
SPRY Technical Analysis | Trend, Signals & Chart Patterns | ARS PHARMACEUTICALS INC (NASDAQ:SPRY) - ChartMill
Food Allergy Market Expected to Experience Accelerated Growth - openPR.com
[Form 3] ARS Pharmaceuticals, Inc. Initial Statement of Beneficial Ownership - Stock Titan
ARS Pharmaceuticals Hits Day High with 10.59% Surge in Stock Price - Markets Mojo
Cantor Fitzgerald raises ARS Pharmaceuticals stock price target on CSU program potential By Investing.com - Investing.com South Africa
Cantor Fitzgerald raises ARS Pharmaceuticals stock price target on CSU program potential - Investing.com India
ARS Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald - Moomoo
Liquidity Mapping Around (SPRY) Price Events - Stock Traders Daily
Creek Drive Management Group LLC's ARS Pharmaceuticals Inc(SPRY) Holding History - GuruFocus
Number of shareholders of ARS Pharmaceuticals, Inc. – NASDAQ:SPRY - TradingView
SPRY Stock Price, Quote & Chart | ARS PHARMACEUTICALS INC (NASDAQ:SPRY) - ChartMill
Ars Pharmaceuticals’ Earnings Call Highlights Growth and Risks - TipRanks
ARS Pharmaceuticals: Still A Buy As Neffy Access Improves (NASDAQ:SPRY) - Seeking Alpha
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q1 2026 Earnings Call Transcript - Insider Monkey
ARS Pharmaceuticals gears up for Q1 print; here are the recent forecast changes from Wall Street's most accurate analysts - MSN
ARS Pharma (SPRY) Q1 2026 Earnings Transcript - AOL.com
Why (SPRY) Price Action Is Critical for Tactical Trading - Stock Traders Daily
ARS Pharmaceuticals, Inc. (SPRY) reports Q1 loss, beats revenue estimates - MSN
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by ARS Investment Partners LLC - MarketBeat
ARS Pharmaceuticals Q1 earnings call highlights - MSN
Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT), Neurogene (NGNE) and ARS Pharmaceuticals (SPRY) - The Globe and Mail
ARS Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
SPRY SEC FilingsARS Pharms 10-K, 10-Q, 8-K Forms - Stock Titan
ARS Pharmaceuticals Q1 2026 Results: neffy® Drives $22.7M Revenue, U.S. and Global Expansion Updates - Minichart
Ars Pharmaceuticals Inc (SPRY) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):